Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06437639
Status:
COMPLETED
Last Update Posted:
2024-05-31
First Post:
2024-05-24
Brief Title:
MEXIDOL Sequential Therapy of Patients With Primary Open-angle Glaucoma POAG
Sponsor:
Pharmasoft
Organization:
Pharmasoft
Study Overview
Official Title:
Prospective Open Comparative Randomized Study of the Efficacy and Safety Evaluation of the Mexidol Sequential Therapy of Patients With Primary Open-angle Glaucoma POAG
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hypothesis The use of neurocytoprotectors helps restore the functional activity of mitochondria improve the nervous activity of the retina and optic nerve and stabilize the glaucomatous process
Detailed Description:
Hypothesis Mexidol allows to optimize POAG therapy by reducing mitochondrial dysfunction and stabilizing glaucomatous optic neuropathy by improving the functional activity of mitochondria and its energy-producing function
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None